middle.news
Neuren’s DAYBUE Sales Surge 30% in Q2, Lifting 2026 Royalty Forecast
9:52am on Wednesday 5th of August, 2026 AEST
•
Pharmaceuticals
Read Story
Neuren’s DAYBUE Sales Surge 30% in Q2, Lifting 2026 Royalty Forecast
9:52am on Wednesday 5th of August, 2026 AEST
Key Points
Q2 2026 DAYBUE net sales rose 30% year-on-year to US$125 million
Strong volume growth fueled by DAYBUE STIX powder formulation adoption
European launch anticipated in early Q4 2026 pending approval
Japan trial readout expected Sept-Nov 2026 with 2027 submission planned
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE